Virbac SA (VRBCF)
USD 324.0
(0.0%)
USD 324.0
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 40.64 Million EUR | -10.46% |
| 2022 | 45.38 Million EUR | 6.52% |
| 2021 | 42.61 Million EUR | -44.95% |
| 2020 | 77.39 Million EUR | -76.65% |
| 2019 | 331.45 Million EUR | -11.6% |
| 2018 | 374.93 Million EUR | -8.28% |
| 2017 | 408.77 Million EUR | -5.76% |
| 2016 | 433.74 Million EUR | -16.71% |
| 2015 | 520.78 Million EUR | 132.39% |
| 2014 | 224.09 Million EUR | 20.59% |
| 2013 | 185.83 Million EUR | 27.74% |
| 2012 | 145.48 Million EUR | 98.91% |
| 2011 | 73.14 Million EUR | 124.97% |
| 2010 | 32.51 Million EUR | -5.85% |
| 2009 | 34.53 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 67.37 Million EUR | 721.08% |
| 2005 | 8.2 Million EUR | -82.13% |
| 2004 | 45.91 Million EUR | -24.45% |
| 2003 | 60.76 Million EUR | 28.9% |
| 2002 | 47.14 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 183.45 Million EUR | 351.65% |
| 2024 Q2 | 183.45 Million EUR | 0.0% |
| 2023 Q1 | 87.22 Million EUR | 92.17% |
| 2023 Q4 | 40.64 Million EUR | -38.07% |
| 2023 Q3 | 65.61 Million EUR | -24.77% |
| 2023 Q2 | 87.22 Million EUR | 0.0% |
| 2023 FY | 40.64 Million EUR | -10.46% |
| 2022 Q4 | 45.38 Million EUR | 0.0% |
| 2022 Q1 | 93.05 Million EUR | 118.39% |
| 2022 FY | 45.38 Million EUR | 6.52% |
| 2022 Q2 | 92.67 Million EUR | -0.41% |
| 2022 Q3 | 45.38 Million EUR | -51.03% |
| 2021 FY | 42.61 Million EUR | -44.95% |
| 2021 Q1 | 46.08 Million EUR | -40.45% |
| 2021 Q3 | 43.4 Million EUR | -4.94% |
| 2021 Q4 | 42.61 Million EUR | -1.84% |
| 2021 Q2 | 45.66 Million EUR | -0.93% |
| 2020 FY | 77.39 Million EUR | -76.65% |
| 2020 Q2 | 350.79 Million EUR | -0.79% |
| 2020 Q4 | 77.39 Million EUR | -1.37% |
| 2020 Q1 | 353.6 Million EUR | 6.68% |
| 2020 Q3 | 78.47 Million EUR | -77.63% |
| 2019 Q4 | 331.45 Million EUR | -0.45% |
| 2019 Q2 | 420.14 Million EUR | -0.41% |
| 2019 Q3 | 332.95 Million EUR | -20.75% |
| 2019 Q1 | 421.86 Million EUR | 12.52% |
| 2019 FY | 331.45 Million EUR | -11.6% |
| 2018 Q3 | 375.89 Million EUR | -13.9% |
| 2018 Q1 | 437.3 Million EUR | 6.98% |
| 2018 FY | 374.93 Million EUR | -8.28% |
| 2018 Q4 | 374.93 Million EUR | -0.26% |
| 2018 Q2 | 436.56 Million EUR | -0.17% |
| 2017 Q4 | 408.77 Million EUR | -0.21% |
| 2017 FY | 408.77 Million EUR | -5.76% |
| 2017 Q2 | 485.51 Million EUR | -0.39% |
| 2017 Q1 | 487.38 Million EUR | 12.37% |
| 2017 Q3 | 409.63 Million EUR | -15.63% |
| 2016 Q1 | 554.55 Million EUR | 6.48% |
| 2016 FY | 433.74 Million EUR | -16.71% |
| 2016 Q4 | 433.74 Million EUR | -0.56% |
| 2016 Q3 | 436.17 Million EUR | -20.34% |
| 2016 Q2 | 547.57 Million EUR | -1.26% |
| 2015 FY | 520.78 Million EUR | 132.39% |
| 2015 Q4 | 520.78 Million EUR | -0.52% |
| 2015 Q1 | 593.89 Million EUR | 165.01% |
| 2015 Q3 | 523.51 Million EUR | -10.62% |
| 2015 Q2 | 585.72 Million EUR | -1.38% |
| 2014 Q3 | 227.61 Million EUR | -7.88% |
| 2014 Q1 | 247.82 Million EUR | 33.36% |
| 2014 FY | 224.09 Million EUR | 20.59% |
| 2014 Q4 | 224.09 Million EUR | -1.55% |
| 2014 Q2 | 247.09 Million EUR | -0.29% |
| 2013 FY | 185.83 Million EUR | 27.74% |
| 2013 Q4 | 185.83 Million EUR | -0.07% |
| 2013 Q3 | 185.97 Million EUR | -9.99% |
| 2013 Q2 | 206.61 Million EUR | -0.11% |
| 2013 Q1 | 206.84 Million EUR | 42.17% |
| 2012 FY | 145.48 Million EUR | 98.91% |
| 2012 Q4 | 145.48 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q4 | 73.14 Million EUR | 0.0% |
| 2011 FY | 73.14 Million EUR | 124.97% |
| 2010 FY | 32.51 Million EUR | -5.85% |
| 2010 Q2 | 41.17 Million EUR | 0.0% |
| 2010 Q4 | 32.51 Million EUR | 0.0% |
| 2009 Q4 | 34.53 Million EUR | 0.0% |
| 2009 FY | 34.53 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 67.37 Million EUR | 721.08% |
| 2005 FY | 8.2 Million EUR | -82.13% |
| 2004 FY | 45.91 Million EUR | -24.45% |
| 2003 FY | 60.76 Million EUR | 28.9% |
| 2002 FY | 47.14 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 99.818% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 99.894% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | 62.039% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 99.797% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -109.572% |